Table 1 Overview of baseline characteristics in the compared groups; SD = standard deviation, MSM = men who have sex with men, HPC = patients from countries of high HIV prevalence, ART = antiretroviral therapy, IQR = interquartile range, NNRTI = antiretroviral regimen based on NNRTI, PI = antiretroviral regimen based on PI, NRTI or NNRTI/PI = antiretroviral regimen either consisting of NRTI only or including NNRTI and PI; p-values calculated by T-test, Chi-squared or Mann-Whitney-U test
TE (n = 61) | PCP (n = 196) | p | |||
|---|---|---|---|---|---|
n/mean | %/SD | n/mean | %/SD | ||
Age | 40.8 | 8.4 | 41.0 | 10.5 | 0.876 |
Female | 16 | 26.2% | 28 | 14.3% | 0.031 |
Migrant | 13 | 21.3% | 41 | 20.9% | 0.948 |
Transmission risk | |||||
MSM | 25 | 41.0% | 114 | 58.2% | 0.013 |
HPC | 11 | 18.0% | 14 | 7.1% | |
Other | 25 | 41.0% | 68 | 34.7% | |
ART initiation date | Apr 02 (median) | 34 months (IQR) | Sep 01 (median) | 35 months (IQR) | 0.631 |
Firstline-ART | |||||
NNRTI | 11 | 18.0% | 34 | 17.3% | 0.069 |
PI | 45 | 73.8% | 119 | 60.7% | |
NNRTI/PI | 3 | 4.9% | 37 | 18.9% | |
NRTI | 2 | 3.3% | 6 | 3.1% | |
Baseline values | |||||
CD4/μl | 60.9 | 44.2 | 44.7 | 42.1 | 0.022 |
CD8/μl | 637.2 | 301.2 | 726.4 | 492.3 | 0.222 |
%CD4 | 6.8 | 4.3 | 4.8 | 3.9 | 0.013 |
%CD8 | 67.0 | 13.3 | 65.2 | 15.9 | 0.565 |
VL (log10 Kop/ml) | 4.46 | 1.20 | 5.00 | 1.02 | 0.008 |
Lymphocytes/μl | 981.8 | 544.1 | 1,056.0 | 887.39 | 0.635 |